Information  X 
Enter a valid email address

Company Name matching 'uniQure Inc'

Date
Time Source
Company
Announcement
08 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
05 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
01 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure to Participate in Multiple Upcoming Industry Conferences in April
29 Mar 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
01 Mar 2021 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
26 Feb 2021 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in March
08 Feb 2021 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
01 Feb 2021 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in February
21 Dec 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
08 Dec 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
07 Dec 2020 9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
02 Dec 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in December
30 Nov 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
19 Nov 2020 2:10 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
04 Nov 2020 3:46 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
  12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in November
27 Oct 2020 11:05 am GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
13 Oct 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
30 Sep 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in October
25 Sep 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
03 Sep 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in September
26 Aug 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
30 Jul 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
24 Jun 2020 9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
19 Jun 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
17 Jun 2020 9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
15 Jun 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Change for its 2020 Annual General Meeting of Shareholders
14 May 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
29 Apr 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
28 Apr 2020 9:51 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting
17 Apr 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors
30 Mar 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Investor Conferences in April
26 Mar 2020 11:00 am GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
03 Mar 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in March
02 Mar 2020 9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
  9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
27 Feb 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
04 Feb 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
31 Jan 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in February
19 Dec 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
08 Dec 2019 9:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
02 Dec 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in December
06 Nov 2019 2:16 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
05 Nov 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy
01 Nov 2019 11:00 am GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in November
31 Oct 2019 11:00 am GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
28 Oct 2019 11:00 am GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
27 Sep 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in October
06 Sep 2019 1:39 am GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Pricing of its Public Offering
04 Sep 2019 9:02 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Proposed Public Offering
03 Sep 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
30 Aug 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in September
20 Aug 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Leadership Promotions and Executive Transition
29 Jul 2019 12:18 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress
26 Jul 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
06 Jul 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
21 Jun 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
31 May 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences
22 May 2019 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
10 May 2019 1:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t